COMPARISON OF CHOLECALCIFEROL VERSUS DOXERCALCIFEROL IN THE TREATMENT OF SECONDA

胆钙化醇与多克骨化醇治疗第二次发作的比较

• 批准号: 7606475
• 负责人: Akber Saifullah
• 金额: $ 1.01万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606475
• 关键词: Blood Pressure; Calcitriol; Cholecalciferol; Chronic Kidney Failure; Computer Retrieval of Information on Scientific Projects Database; Dialysis procedure; Doxercalciferol; End Point; Ergocalciferols; Foundations; Funding; Grant; Guidelines; Hyperparathyroidism; Institution; Kidney; Measures; Pain; Parathyroid Hormones; Patients; Personal Satisfaction; Physical Dialysis; Population; Quality of life; Renal function; Research; Research Personnel; Resources; Secondary Hyperparathyroidism; Source; Staging; Supplementation; United States National Institutes of Health; Vitamin D; Vitamin D2; Well in self; base; compare effectiveness; human PTH protein; improved; muscle strength; paricalcitol

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The majority of patients with moderate to severe chronic kidney disease (CKD) (stages 3 and 4) develop secondary hyperparathyroidism (2¿HPT), but the optimal therapy to control hyperparathyroidism in this group is unknown. The National Kidney Foundation presented guidelines in 2003 recommending vitamin D supplementation for vitamin D insufficient patients and active vitamin D therapy in patients with sufficient levels. These guidelines are based on opinion since there are no significant trials to determine if vitamin D supplementation is effective in this population. The active vitamin D metabolites doxercalciferol, paricalcitol, and calcitriol have been shown to effectively suppress parathyroid hormone (PTH), but have not been compared with vitamin D supplementation with a calciferol (ergocalciferol or cholecalciferol). Beyond hyperparathyroidism, small studies suggest vitamin D replacement in vitamin D insufficient non-CKD subjects result in improved pain, feeling of well being, blood pressure and strength. In this proposed study we wish to directly compare the effectiveness of cholecalciferol versus doxercalciferol in suppressing elevated PTH levels in subjects with CKD not on dialysis who have vitamin D insufficiency in a three month study. Secondary endpoints will be change in muscle strength, blood pressure, renal function, and quality of life measures..

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 大多数中度至重度慢性肾病（CKD）（3期和4期）患者发生继发性甲状旁腺功能亢进（2 <$HPT），但控制该组甲状旁腺功能亢进的最佳治疗方法尚不清楚。 国家肾脏基金会在2003年提出了指南，建议为维生素D不足的患者补充维生素D，并为维生素D水平充足的患者提供积极的维生素D治疗。 这些指南是基于意见，因为没有重要的试验来确定维生素D补充剂是否对这一人群有效。 活性维生素D代谢物度骨化醇、帕立骨化醇和骨化三醇已被证明可有效抑制甲状旁腺激素（PTH），但尚未与维生素D补充剂和骨化醇（麦角钙化醇或胆钙化醇）进行比较。 除了甲状旁腺功能亢进，小型研究表明，维生素D不足的非CKD受试者的维生素D替代治疗可改善疼痛、健康感、血压和力量。 在这项拟定的研究中，我们希望在一项为期3个月的研究中直接比较胆钙化醇与度钙化醇在抑制维生素D不足的未接受透析的CKD受试者PTH水平升高方面的有效性。 次要终点将是肌力、血压、肾功能和生活质量指标的变化。